Insider Selling: CryoPort (NASDAQ:CYRX) Director Sells $358,424.16 in Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 23,214 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the sale, the director owned 67,894 shares of the company’s stock, valued at approximately $1,048,283.36. This represents a 25.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

CryoPort Stock Down 2.8%

NASDAQ:CYRX opened at $14.77 on Thursday. The stock’s 50 day moving average price is $12.18 and its two-hundred day moving average price is $10.26. The firm has a market capitalization of $744.44 million, a price-to-earnings ratio of 10.94 and a beta of 1.90. CryoPort, Inc. has a 12-month low of $6.16 and a 12-month high of $16.73.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. Equities research analysts expect that CryoPort, Inc. will post -0.85 EPS for the current year.

Analyst Ratings Changes

CYRX has been the subject of several recent analyst reports. KeyCorp upped their price objective on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. BTIG Research boosted their target price on CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Needham & Company LLC boosted their target price on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.11.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently added to or reduced their stakes in CYRX. LPL Financial LLC boosted its stake in shares of CryoPort by 6.6% in the 4th quarter. LPL Financial LLC now owns 23,306 shares of the company’s stock valued at $224,000 after purchasing an additional 1,433 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of CryoPort by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after buying an additional 1,557 shares during the period. State of Wyoming grew its position in shares of CryoPort by 30.2% during the 2nd quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after buying an additional 3,301 shares during the period. Basepoint Wealth LLC acquired a new stake in shares of CryoPort during the 4th quarter worth approximately $34,000. Finally, BNP Paribas Financial Markets grew its position in shares of CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock worth $113,000 after buying an additional 4,225 shares during the period. 92.90% of the stock is owned by institutional investors.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.